Slingshot members are tracking this event:

Phase 3 data of Auryxia for Iron deficiency anemia in non-dialysis dependent CKD patients due early 2Q 2016. April 30 is a BPC estimate based on early 2Q guidance

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
KERX Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 29, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Study In Pancreatic Cancer, Auryxia, Iron Deficiency, Anemia, Ckd, 2q